Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A wide range of neuropsychiatric side effects are attributed to propranolol including visual hallucinations, somnulence, memory impairment, decrease in response time, dizziness, confusional states, insomnia, nightmares, fatigue, sedation and depression. Benson et al., in a summary review of several clinical studies of 5,846 patients being treated with a variety of beta adrenergic blocking agents, listed depression as a rare side effect of propranolol that was usually reported only after long term treatment at high doses. Despite the widely circulated attribution that depression is a side effect of propranolol, there is a paucity of evidence to directly link this drug with clinically significant mood disturbance. For example, the most widely quoted reference attributing propranolol as a depressogenic agent was a "letter to the editor" which was a retrospective, uncontrolled, unblinded study that did not use a standardized depression rating scale. Most of the evidence linking propranolol to depressive symptoms have derived from scattered case reports in which the onset of depressive symptoms were attributed to this agent. Given the well known cyclic onset and remissions of affective disorders, and the prevalence of depression in the general medical population as a whole, the role of propranolol in these cases is debatable.
 ...
PMID:Propranolol and depression: a reevaluation based on a pilot clinical trial. 640 May 97

Forty outpatients with primary depression were randomly assigned on a double-blind basis to treatment with amitriptyline (a tricyclic antidepressant) or clovoxamine (a nontricyclic, experimental antidepressant). Memory and depression were assessed during a pretreatment baseline period and at the end of days 4, 7, and 28 of drug treatment. A signal detection recognition memory task and conventional memory measures (including the Benton Visual Retention, Wechsler Logical Memory, and verbal learning tests) were used to assess memory. Although both drugs led to comparable clinical improvement in depression, they affected memory performance differently. The signal detection recognition memory task detected an impairment in memory after chronic amitriptyline administration, as contrasted with an improvement in memory after chronic administration of clovoxamine. The memory impairment in the amitriptyline group and improvement in the clovoxamine group were the result of changes in sensitivity [P(A)]. No changes in response bias (B) were detected. Conventional memory tests failed to detect drug-related differences in memory between the two groups. On the Benton, errors decreased over time within both drug treatment groups, whereas correct reproductions increased within the amitriptyline group only. However, between-group differences on the Benton did not reach significance. Results from the signal detection task suggest an amitriptyline-associated memory impairment. However, this interpretation is tempered by the finding that conventional memory measures failed to detect differences in memory performance between the two groups. We discuss the limitations of traditional memory measures and the utility of a signal detection approach in studies of psychopharmacologic influences on memory.
 ...
PMID:Effects of two antidepressants on memory performance in depressed outpatients: a double-blind study. 643 86

Of a group of 288 depressed female inpatients, 43 (15%) had secondary panic attacks. Compared to other depressives, the subgroup with panic attacks had significantly higher frequencies of anorexia, weight loss, gastrointestinal disturbances, hypochondriasis, and psychomotor agitation, and significantly lower frequencies of melancholic symptoms, including loss of interest in usual activities, guilt feelings, delusional thinking, psychomotor retardation, and orientation or memory impairment. Patients with panic attacks were less likely to have a depressed parent and were more likely to be described as having been nervous, worrisome, sensitive, and sexually dysfunctional before the onset of depression. Phenomenologically, they resembled "anxious depressives" as described by other authors.
 ...
PMID:Depressed women with panic attacks. 646 19

1. A double-blind study of the effect of CDP-choline on memory impairment following bilateral ECT was performed on 22 inpatients suffering from endogenous depression. 2. Memory scores were checked after 2 and 4 ECT sessions, and the length of the post-ECT confusional state was also measured. 3. The results show no statistically significant differences between the reduced memory scores obtained by both groups. Our findings do not support the hypothesis that CDP-choline affords protection against ECT-induced memory dysfunction in depression cases.
 ...
PMID:The value of cytidine-5-diphosphate-choline in the prevention of impairment of memory function after electric convulsive therapy. A double-blind study. 675 60

This study investigated whether depressed subjects differ from controls in their ability to appreciate emotional aspects of verbal material, or in their use of emotional qualities of stimuli in learning and remembering. When asked to rate the degree of emotionality of words, depressed subjects did so essentially identically with controls. However, despite apparently similar evaluatory processing, the depressed failed to remember as well as controls. Depressed subjects were more dependent than controls on both high emotionality and high stimulus concreteness for recognition memory, but were less benefited by these properties in free recall. While providing no evidence for deficits specific to emotionality, our results suggest that relatively shallow processing of semantic aspects of stimuli may be an important factor in the memory impairment of depression.
 ...
PMID:Processing of emotional properties of stimuli by depressed and normal subjects. 684 42

This paper analyses the pattern of use of and the response to electroconvulsive therapy (ECT) in an Indian rural teaching general hospital between 1977 and 1980. ECT was used in 503 cases (14.3 per cent of 3,517). Three-quarters of the patients to whom it was given were schizophrenic, one-fifth depressed and 6 per cent suffering from post-partum psychosis. Though the treatment gave the best results in depression it was also effective in many schizophrenics and post-partum psychotics. The commonest side effect was memory impairment. Following unmodified ECT severe confusion and excitement were frequent, while thrombophlebitis, bronchospasm, prolonged apnoea and peripheral circulatory collapse occurred only with the modified technique. The usefulness of ECT in developing countries like India is highlighted.
 ...
PMID:Electroconvulsive therapy in a rural teaching general hospital in India. 733 65

The prevalence rate of subjective memory impairment (SMI) and its value as a predictor of future depression or dementia was studied in a community sample of elderly residents in one electoral ward using the short-CARE. SMI was found to be common, occurring in 25% of subjects. Subjects with SMI were more likely to be suffering from either dementia or depression than those without the complaint, although 60% of subjects with SMI did not have evidence of either disorder. When followed up over a 2-year period, subjects with SMI were found to be at four-fold greater risk of developing future dementia and two-fold greater risk of developing a depression compared with those without SMI. The SMI scale was not found to be useful as a population screen for dementia or depression, although two of the nine items might have value as screening questions in clinical circumstances to determine those with memory complaints at risk for dementia.
 ...
PMID:The Gospel Oak Study stage IV: the clinical relevance of subjective memory impairment in older people. 748 Apr 55

This paper describes the design and first results of the cross-sectional phase of a study on memory impairment in elderly subjects (Pavia Memory Project). The target population consisted of the 1,046 subjects born in 1925 and currently living in Pavia. Four hundred and thirty-six subjects (plus 287 interviewed at home) participated in the first stage, which consisted of a semi-structured anamnestic interview. The 400 interviewed subjects with none of the exclusion criteria participated in the second stage, which consisted of a memory test battery, a standardized neurological examination and screening procedures for depression (GDS) and dementia (MMSE). On the basis of the memory scores, three groups were defined: memory impairment (MI: 8.8%), mild memory impairment (MMI: 39.8%); normal (N: 51.3%). There were more failures on the visuo-spatial memory tests. Depression was equally distributed in the N and MI groups (about 15%), but was more frequent in the MMI group (27%). Abnormal neurological signs were largely independent of memory performance. Two cohorts (of MI and N subjects) underwent neuropsychological and instrumental (CT-scan, EEG, ERPs, eye movements) assessment, which will be regularly repeated in the longitudinal phase.
 ...
PMID:Pavia memory project: study design and first results. 755 67

Alzheimer's disease (AD) primarily results in memory impairment and cognitive deficits in areas such as language, visuospatial function, calculation, praxis and judgement. However, over 30% of patients with dementia develop a group of secondary behavioural disturbances, including depression, hallucinations and delusions, agitation, insomnia and wandering. Because these secondary symptoms impair patients' function, increase their need for supervision, and often influence the decision to institutionalise them, the control of these symptoms is a priority in managing AD. Psychotropic drugs, particularly antipsychotics (neuroleptics), have been a mainstay in treating many of these symptoms, but carry a high risk of adverse effects. Patients with AD may be particularly vulnerable to adverse effects of medications because of changes in pharmacokinetics and neurotransmitter systems, related to both AD and aging. At present, treating secondary symptoms of AD is more of an art than a science. For virtually every group of symptoms, older and newer classes of medications are available, with proven efficacy in patients without dementia and less clear results in AD patients. We review current treatment options and suggest preferences for each symptom complex, based on a trade-off between efficacy and adverse effects. New agents, such as selective serotonin reuptake inhibitors and atypical antipsychotics, may herald the arrival of symptom- (and receptor-) specific drugs with minimal adverse effects.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Adjunctive therapy in patients with Alzheimer's disease. A practical approach. 757 86

This study evaluated Alzheimer disease (AD) patients' awareness of impairment in several domains, including cognitive, psychiatric, and behavioral functioning. Ratings made by 13 patients with moderate to moderately severe probable AD were compared with ratings made by their relatives using the Cognitive Behavior Rating Scales (Williams et al., 1985; Williams, 1987). Unawareness was defined as the discrepancy between informant and patient ratings. Informants consistently rated patients' impairment as more severe than the patients rated themselves. However, the discrepancy between the ratings was statistically significant only for Language Disorder, Higher Cognitive Deficits, Memory Disorder, Dementia, and Apraxia, and not for Agitation, Need for Routine, Depression, and Disorientation scales. Unawareness was not related to severity of memory impairment, as measured by the Rivermead Behavioural Memory Test (Wilson et al., 1985). The results of this small, preliminary study of relatively severely impaired AD patients suggest that awareness of psychiatric and behavioral problems may be relatively preserved compared to awareness of cognitive problems. These findings should be replicated with a larger sample with a broader range of severity.
 ...
PMID:Anosognosia in Alzheimer disease. 760 23


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>